Souhaitez-vous accéder aux communiqués récents ?

First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany,...

Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis...

Avance Clinical is delivering the GlobalReady solution to help biotechs de-risk, conserve capital and accelerate drug development programs.

Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics, today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an...

Avance Clinical, the award-winning, global CRO for biotechs, is proud to announce its sponsorship of the Citeline Awards 2025 tomorrow in Boston.

Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The...

BOSTON, MA, April 10, 2025 (GLOBE NEWSWIRE) -- Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day...

Global Reach for US Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites

Phase III study showed sustained proteinuria reduction at one year with favorable safety1Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause...

Global Reach for US Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites